X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1589) 1589
Publication (132) 132
Book Review (75) 75
Newsletter (10) 10
Magazine Article (8) 8
Book Chapter (4) 4
Conference Proceeding (4) 4
Newspaper Article (4) 4
Data Set (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
glatiramer acetate (1438) 1438
humans (1313) 1313
multiple sclerosis (998) 998
index medicus (752) 752
peptides - therapeutic use (746) 746
multiple sclerosis - drug therapy (703) 703
clinical neurology (607) 607
female (596) 596
immunosuppressive agents - therapeutic use (530) 530
male (502) 502
adult (500) 500
interferon-beta - therapeutic use (485) 485
neurosciences (426) 426
double-blind (413) 413
multiple sclerosis, relapsing-remitting - drug therapy (374) 374
middle aged (329) 329
animals (320) 320
treatment outcome (295) 295
placebo-controlled trial (290) 290
immunologic factors - therapeutic use (287) 287
neurology (268) 268
adjuvants, immunologic - therapeutic use (260) 260
experimental autoimmune encephalomyelitis (251) 251
pharmacology & pharmacy (250) 250
interferon beta-1a (237) 237
multiple sclerosis - immunology (228) 228
magnetic resonance imaging (227) 227
interferon-beta (211) 211
immunology (209) 209
disease progression (208) 208
natalizumab (201) 201
interferon beta-1b (197) 197
disability (196) 196
drug therapy (181) 181
multicenter (180) 180
care and treatment (164) 164
multiple-sclerosis (161) 161
therapy (156) 156
glatiramer acetate - therapeutic use (149) 149
central-nervous-system (146) 146
interferon (145) 145
research (145) 145
myelin basic-protein (143) 143
interferon beta (137) 137
mice (131) 131
multiple sclerosis - therapy (130) 130
experimental allergic encephalomyelitis (125) 125
copolymer 1 (124) 124
medicine & public health (122) 122
young adult (121) 121
analysis (119) 119
multiple sclerosis - pathology (118) 118
peptides - adverse effects (118) 118
disease (115) 115
multiple sclerosis - physiopathology (115) 115
time factors (114) 114
adolescent (110) 110
immunosuppressive agents - adverse effects (107) 107
multiple sclerosis - diagnosis (107) 107
recurrence (106) 106
t-cells (106) 106
peptides - pharmacology (105) 105
disability evaluation (103) 103
health aspects (101) 101
clinical trials as topic (100) 100
retrospective studies (99) 99
peptides - administration & dosage (98) 98
psychiatry (94) 94
relapse rate (90) 90
brain - pathology (89) 89
mitoxantrone - therapeutic use (89) 89
medicine, general & internal (88) 88
immunotherapy (87) 87
immunosuppressive agents - administration & dosage (83) 83
clinical trials (82) 82
progressive multifocal leukoencephalopathy (82) 82
drug therapy, combination (81) 81
fingolimod (81) 81
inflammation (80) 80
biological response modifiers (79) 79
disease models, animal (78) 78
encephalomyelitis, autoimmune, experimental - drug therapy (78) 78
antibodies, monoclonal - therapeutic use (77) 77
cytokines (77) 77
immunomodulation (77) 77
multiple sclerosis, relapsing-remitting - immunology (77) 77
mri (76) 76
diagnostic-criteria (75) 75
neuroprotection (75) 75
randomized controlled trials as topic (75) 75
dosage and administration (74) 74
multiple sclerosis, relapsing-remitting - pathology (74) 74
follow-up studies (73) 73
copaxone (71) 71
neuroprotective agents - therapeutic use (71) 71
remitting multiple-sclerosis (71) 71
follow-up (68) 68
development and progression (67) 67
interferon-beta - administration & dosage (67) 67
mitoxantrone (67) 67
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1475) 1475
Russian (38) 38
German (31) 31
Spanish (24) 24
Japanese (11) 11
French (9) 9
Hungarian (7) 7
Finnish (5) 5
Polish (4) 4
Italian (2) 2
Chinese (1) 1
Czech (1) 1
Dutch (1) 1
Hebrew (1) 1
Norwegian (1) 1
Portuguese (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Brain, ISSN 0006-8950, 11/2015, Volume 138, Issue 11, pp. 3275 - 3286
Journal Article
Journal of the Neurological Sciences, ISSN 0022-510X, 2015, Volume 359, Issue 1, pp. 24 - 34
Journal Article
Nature Reviews Neurology, ISSN 1759-4758, 01/2016, Volume 12, Issue 1, pp. 5 - 6
A randomized, double-blind, phase III trial of generic glatiramer acetate has shown equivalent efficacy and safety compared with the approved formulation,... 
Female | Male | Glatiramer Acetate - therapeutic use | Humans | Immunosuppressive Agents - therapeutic use | Multiple Sclerosis - drug therapy
Journal Article
Clinical Therapeutics, ISSN 0149-2918, 2015, Volume 37, Issue 4, pp. 691 - 715
Abstract Purpose Interferon injectables and glatiramer acetate have served as the primary disease-modifying treatments for multiple sclerosis (MS) since their... 
Internal Medicine | Medical Education | cost | disease-modifying treatments | multiple sclerosis | new drugs | pharmacotherapy | cost disease-modifying treatments multiple sclerosis new drugs pharmacotherapy | PEGYLATED INTERFERON BETA-1A | COST-EFFECTIVENESS | ORAL FINGOLIMOD FTY720 | PLACEBO-CONTROLLED PHASE-3 | INTRAMUSCULAR INTERFERON | CLINICAL-EFFICACY | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | GLATIRAMER ACETATE | BG-12 DIMETHYL FUMARATE | QUALITY-OF-LIFE | United States | Humans | Immunosuppressive Agents - therapeutic use | Drug Approval | Polyethylene Glycols - economics | Polyethylene Glycols - therapeutic use | Interferon-beta - therapeutic use | Antibodies, Monoclonal, Humanized - economics | Dimethyl Fumarate - economics | Drug Costs - statistics & numerical data | Immunosuppressive Agents - economics | Fingolimod Hydrochloride - therapeutic use | Toluidines - economics | United States Food and Drug Administration | Fingolimod Hydrochloride - economics | Toluidines - therapeutic use | Antibodies, Monoclonal, Humanized - therapeutic use | Multiple Sclerosis - economics | Alemtuzumab | Interferon-beta - economics | Crotonates - therapeutic use | Crotonates - economics | Dimethyl Fumarate - therapeutic use | Glatiramer Acetate - therapeutic use | Glatiramer Acetate - economics | Multiple Sclerosis - drug therapy | Multiple sclerosis | Care and treatment | Biological response modifiers | Drug approval | Interferon | FDA approval | Drug therapy
Journal Article
Multiple Sclerosis Journal, ISSN 1352-4585, 08/2015, Volume 21, Issue 9, pp. 1159 - 1171
Journal Article
Journal of Neurology, ISSN 0340-5354, 12/2018, Volume 265, Issue 12, pp. 2980 - 2992
Journal Article
JAMA - Journal of the American Medical Association, ISSN 0098-7484, 01/2019, Volume 321, Issue 2, pp. 175 - 187
Journal Article